Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
CI-1040
Description:
CI-1040 is an experimental anticancer drug that inhibits MEK enzymes in the MAPK signaling pathway.
Primary topic:
Melanoma and MAPK Pathways (26%)
Related topics:
Melanoma and MAPK Pathways (26%),
Acute Myeloid Leukemia Research (7%)
Wikidata ID:
wiki/Q27076005
OpenAlex ID:
keywords/ci-1040
Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer
2004
·
John Rinehart
, Alex A. Adjei
, et al.
·
Journal of Clinical Oncology
·
688
Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies
2005
·
Patricia M. LoRusso
, Alex A. Adjei
, et al.
·
Journal of Clinical Oncology
·
421
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
2008
·
Stephen D. Barrett
, Alexander J. Bridges
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
321
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
2003
·
L ALLEN
, Judith Sebolt-Leopold
, et al.
·
Seminars in Oncology
·
275
Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models
2007
·
Hongbin Ji
, Zhenxiong Wang
, et al.
·
Cancer Research
·
185
PDF
Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells
2009
·
Jane J. Yu
, Victoria A. Robb
, et al.
·
Proceedings of the National Academy of Sciences
·
167
Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
2008
·
Kwong-Kwok Wong
·
Recent Patents on Anti-Cancer Drug Discovery
·
167
RETRACTED ARTICLE: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
2011
·
M Konopleva
, M Milella
, et al.
·
Leukemia
·
151
PDF
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
2003
·
Eric A Collisson
, Abhijit De
, et al.
·
PubMed
·
143
Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations
2005
·
Gudrun Pohl
, Chung-Liang Ho
, et al.
·
Cancer Research
·
132
PDF
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
2009
·
C L Mahoney
, B Choudhury
, et al.
·
British Journal of Cancer
·
131
PDF
Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
2008
·
Robert A. Cartlidge
, G. R. Thomas
, et al.
·
Pigment Cell & Melanoma Research
·
129
PDF
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
2008
·
N Nakayama
, K Nakayama
, et al.
·
British Journal of Cancer
·
125
PDF
MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
2004
·
Judith Sebolt-Leopold
·
Current Pharmaceutical Design
·
125
Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human Heterotransplants
2005
·
Hayley M. McDaid
, Lluis Lopez-Barcons
, et al.
·
Cancer Research
·
100
PDF
Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy
2008
·
Ker Yu
, Lourdes Toral-Barza
, et al.
·
Cancer Biology & Therapy
·
96
PDF
Attenuation of MCP-1/CCL2 expression ameliorates neuropathy in a mouse model for Charcot–Marie–Tooth 1X
2010
·
Janos Groh
, Kristina Heinl
, et al.
·
Human Molecular Genetics
·
94
Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
2007
·
Marie-Emmanuelle Legrier
, Chia-Ping Huang Yang
, et al.
·
Cancer Research
·
94
Increase of MCP‐1 (CCL2) in myelin mutant Schwann cells is mediated by MEK‐ERK signaling pathway
2008
·
Stefan Fischer
, Andreas Weishaupt
, et al.
·
Glia
·
76
Inhibitory Effects of the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 on the Proliferation and Tumor Growth of Thyroid Cancer Cells withBRAForRASMutations
2007
·
Dingxie Liu
, Zhi Liu
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
75
Sparse multitask regression for identifying common mechanism of response to therapeutic targets
2010
·
Kai Zhang
, Joe W. Gray
, et al.
·
Bioinformatics
·
65
PDF
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer
2011
·
Ali Naderi
, Kee Ming Chia
, et al.
·
Breast Cancer Research
·
63
PDF
The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo
2017
·
Emanuel Haasbach
, Christin Müller
, et al.
·
Antiviral Research
·
59
PDF
A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040
2005
·
Yuli Wangab
, Keri Van Becelaere
, et al.
·
Neoplasia
·
58
PDF
Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro
2003
·
Xue Wei Meng
, Joya Chandra
, et al.
·
Journal of Biological Chemistry
·
58
Show more works
View as search
Works count:
123
Citation count:
4,966
Year
Topic
Type